Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celestial Seasonings 60-Count Supplement Sales "Break Even"

This article was originally published in The Tan Sheet

Executive Summary

Celestial Seasonings 60-count dietary supplement line posted "break even" sales revenues in the fourth quarter ended Sept. 30, a result the specialty tea manufacturer hopes will continue into FY 2000.

You may also be interested in...



Celestial Seasonings supplements launch brewing with $20 mil. in marketing support.

CELESTIAL SEASONINGS DIETARY SUPPLEMENTS LAUNCH BREWING WITH $20 MIL. in introductory advertising and promotional support. The Boulder, Colo.-based company plans to leverage its well-known herbal tea franchise with the launch of Celestial Seasonings brand single ingredient dietary supplements and combination herbal and vitamin products. Scheduled to begin shipping to mass market, grocery, chain drug and health food stores before the end of March, the products are expected to be on-counter in late April. Consumer and trade print and TV advertising, handled by Minneapolis-based Campbell Mithun Esty, will support the launch.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090528

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel